As of November 10, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Iambic Therapeutics, Inc. The largest reported stake is Qatar Investment Authority's, at 5.8%. One filing is on record since November 9, 2026 (Schedule 13G, November 9, 2026).
Sell to companies like Iambic Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Qatar Investment Authority · Sole voting: 2,804,360 · Shared voting: 0 · Sole dispositive: 2,804,360 · Shared dispositive: 0 · SCHEDULE 13G, 2026-11-09
- · Holder: Qatar Investment Authority · Percent: 5.8% · SCHEDULE 13G
- · Holder: Qatar Investment Authority · Percent: 5.8% · Shares: 2,804,360 · SCHEDULE 13G
Iambic Therapeutics, Inc. has 1 Schedule 13D or 13G filing on record since 2026-11-09. 1 holder's latest filing reports 5% or more of common stock, par value $0.001. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Qatar Investment Authority | 5.8% | 2,804,360 | SCHEDULE 13G, 2026-11-09 | 2026-10-15 |
Holding shares or following this stake? See who's behind Iambic Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Watch Iambic Therapeutics, Inc.
Get an email when Iambic Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Iambic Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Iambic Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Iambic Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Qatar Investment Authority | 2,804,360 | 0 | 2,804,360 | 0 | SCHEDULE 13G, 2026-11-09 |
The latest filing identifies Iambic Therapeutics, Inc. by CUSIP 45076A101 and gives its principal executive office as 5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO, CA 92121 (SCHEDULE 13G, 2026-11-09).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-11-09 | Qatar Investment Authority | 5.8% | SCHEDULE 13G |
Also on the record for Iambic Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 15, 2026 | IPO filing, Form 424B4 | $16 a share | IPO filings | Source |
| October 8, 2026 | IPO filing, Form S-1/A | $15 to $17 a share | IPO filings | Source |
| September 21, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| September 9, 2026 | Form D, private offering | $65.97M sold | Form D page | Source |
| April 8, 2026 | Form D, private offering | $27.77M sold | Form D page | Source |
| November 21, 2025 | Form D, private offering | $99.27M sold | Form D page | Source |
Iambic Therapeutics, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Iambic Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.